- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00559637
A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis (MERCUR)
March 8, 2016 updated by: Hoffmann-La Roche
Single-arm, Open Study to Investigate the Efficacy, Safety and Tolerability of Monthly Subcutaneously Administered C.E.R.A. in Patients With Renal Anemia Not Yet Subject to Dialysis and Not Yet Permanently Treated With ESAs
This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in participants with chronic kidney disease who are not treated with erythropoiesis stimulating agent (ESA) and not on dialysis.
Eligible participants will receive Mircera by monthly subcutaneous injections.
The initial dose, based on body weight, will be 1.2 micrograms/kilogram (mcg/kg).
The anticipated time on study treatment is 9-11 months, and the target sample size is 100-500 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
184
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ansbach, Germany, 91522
-
Arnsberg, Germany, 59759
-
Bad Aibling, Germany, 83043
-
Bad Malente, Germany, 23714
-
Berlin, Germany, 10115
-
Bischofswerda, Germany, 01877
-
Bonn, Germany, 53179
-
Dieburg, Germany, 64807
-
Dortmund, Germany, 44135
-
Düsseldorf, Germany, 40211
-
Emsdetten, Germany, 48282
-
Frankfurt, Germany, 60528
-
Friedberg, Germany, 86316
-
Grimma, Germany, 04668
-
Hamburg, Germany, 22391
-
Hamburg, Germany, 21073
-
Heidelberg, Germany, 69120
-
Hilden, Germany, 40721
-
Homburg, Germany, 66424
-
Hoyerswerda, Germany, 02977
-
Jena, Germany, 07743
-
Kaiserslautern, Germany, 67655
-
Koeln, Germany, 50937
-
Köln, Germany, 51109
-
Ludwigslust, Germany, 19288
-
Lörrach, Germany, 79539
-
Lübeck, Germany, 23562
-
Lünen, Germany, 44534
-
Mainz, Germany, 55131
-
Mettmann, Germany, 40822
-
Mühlacker, Germany, 75417
-
München, Germany, 81545
-
Regensburg, Germany, 93053
-
Rheine, Germany, 48431
-
Saarlouis, Germany, 66740
-
Schwandorf, Germany, 92421
-
Schweinfurt, Germany, 97421
-
Sindelfingen, Germany, 71063
-
Sinsheim, Germany, 74889
-
Tangermünde, Germany, 39590
-
Trier, Germany, 54290
-
Tübingen, Germany, 72076
-
ULM, Germany, 89077
-
Velbert, Germany, 42549
-
Wetzlar, Germany, 35578
-
Wiesloch, Germany, 69168
-
Worms, Germany, 67547
-
Wuerzburg, Germany, 97080
-
Würzburg, Germany, 97072
-
Zwickau, Germany, 08056
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- chronic renal anemia;
- hemoglobin value less than or equal to (<=) 10.5 grams/deciliter (g/dL).
Exclusion Criteria:
- prior ESA therapy during previous 3 months;
- acute or chronic bleeding requiring therapy during previous 2 months;
- transfusion of red blood cells during previous 2 months;
- active malignant disease (except non-melanoma skin cancer).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month.
The starting dose will be 1.2 mcg/kg of body weight.
Further dose adjustments will be performed during the study depending on the hemoglobin value.
Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
|
Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month.
The starting dose will be 1.2 mcg/kg of body weight.
Further dose adjustments will be performed during the study depending on the hemoglobin value.
Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL)
Time Frame: Evaluation phase (Months 8 and 9)
|
Participants with both hemoglobin values of the evaluation phase (Months 8 and 9, i.e., Study Days 200-260, values were at least 21 days apart) in the range of 11-12 g/dL were classified as responder.
Participants who received transfusion of erythrocytes between Study Day 139 and 260, or with at least one value missing or outside the range were classified as non-responder for the hemoglobin-range concerned.
|
Evaluation phase (Months 8 and 9)
|
Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-13 g/dL
Time Frame: Evaluation phase (Months 8 and 9)
|
Participants with both hemoglobin values of the evaluation phase (Months 8 and 9, i.e., Study Days 200-260, values were at least 21 days apart) in the range of 11-13 g/dL were classified as responder.
Participants who received transfusion of erythrocytes between Study Day 139 and 260, or with at least one value missing or outside the range were classified as non-responder for the hemoglobin-range concerned.
|
Evaluation phase (Months 8 and 9)
|
Change From Baseline in Hemoglobin Value to the Evaluation Phase
Time Frame: Baseline, evaluation phase (Months 8 and 9)
|
The change from the baseline hemoglobin value to the mean hemoglobin value of the evaluation phase was only calculated if both the baseline value and the mean of the evaluation phase (mean of Months 8 and 9) were available.
In case of only one available hemoglobin value within the evaluation phase, that single value replaced the mean.
|
Baseline, evaluation phase (Months 8 and 9)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Hemoglobin Values in the Range of 11-12 g/dL
Time Frame: Baseline to Month 9
|
The duration of hemoglobin values staying within the range of 11-12 g/dL was defined as the number of (not necessarily consecutive) months with all corresponding hemoglobin values in the respective range.
All months with missing hemoglobin values were counted as months where the hemoglobin value did not stay within the respective range.
|
Baseline to Month 9
|
Duration of Hemoglobin Values in the Range of 11-13 g/dL
Time Frame: Baseline to Month 9
|
The duration of hemoglobin values staying within the range of 11-13 g/dL was defined as the number of (not necessarily consecutive) months with all corresponding hemoglobin values in the respective range.
All months with missing hemoglobin values were counted as months where the hemoglobin value did not stay within the respective range.
|
Baseline to Month 9
|
Time to Increase of Hemoglobin Value to Over 11 g/dL
Time Frame: Baseline to Month 9
|
The duration (number of months) until the hemoglobin value exceeded 11 g/dL for the first time was summarized for participants for whom at least one measured hemoglobin value exceeded 11 g/dL.
|
Baseline to Month 9
|
Total Number of Dose Adjustments
Time Frame: Baseline until Month 8
|
A dose adjustment was defined as a change versus the preceding dose.
It included dose increase, dose reduction and dose interruption.
An interruption (no dose given) was always counted as a dose adjustment, regardless of whether or not at the previous time point a dose had been administered.
After an interruption a change in the dose relative to the dose given before the interruption was counted as a dose adjustment.
|
Baseline until Month 8
|
Total Number of Red Blood Cell (RBC) Transfusions
Time Frame: Baseline to Month 9
|
RBC transfusions could be given during the study, if medically necessary, i.e., in participants with severe anemia with distinct symptoms or signs of anemia (such as in participants with acute blood loss, with severe angina, or whose hemoglobin decreased to critical levels).
|
Baseline to Month 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
November 15, 2007
First Submitted That Met QC Criteria
November 15, 2007
First Posted (Estimate)
November 16, 2007
Study Record Updates
Last Update Posted (Estimate)
April 6, 2016
Last Update Submitted That Met QC Criteria
March 8, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML20888
- 2007-000126-46 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Cornell UniversityUniversity of California, Los AngelesCompletedPregnancy Anemia | Newborn; AnemiaUnited States
-
Peking Union Medical College HospitalRecruiting
Clinical Trials on Methoxy polyethylene glycol-epoetin beta
-
Chugai PharmaceuticalCompleted
-
Hoffmann-La RocheCompletedRenal Insufficiency, Chronic | AnemiaUnited States, Spain, France, Hungary, Italy, Lithuania, Poland
-
Hoffmann-La RocheCompletedAnemiaUnited States, Canada, United Kingdom, Mexico, Poland
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Chugai PharmaceuticalCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedAnemiaItaly, Spain, United States, Germany
-
Hoffmann-La RocheCompleted